Market Cap 8.01M
Revenue (ttm) 0.00
Net Income (ttm) -8.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 63,100
Avg Vol 175,626
Day's Range N/A - N/A
Shares Out 4.83M
Stochastic %K 69%
Beta 0.23
Analysts Sell
Price Target $26.00

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 722 6333
Address:
3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
hiwatt
hiwatt Sep. 7 at 2:49 AM
0 · Reply
hiwatt
hiwatt Sep. 2 at 6:23 PM
$ALZN NEWS--As of 8-25, institutional holdings have jumped to over 57%!!!. After the decline in price in March, institutional dropped to just 3% of the 3.7M shares, or 114K shares. Today with 4.8M shares, institution own 2,750,464 shares, or 57.4%
1 · Reply
austinhaleybop
austinhaleybop Sep. 2 at 3:50 PM
0 · Reply
austinhaleybop
austinhaleybop Sep. 2 at 3:47 PM
$ALZN Todd straight up gangster on ALL his stocks what happened to his YYGH? it's gone!!!??? Joel help me
0 · Reply
austinhaleybop
austinhaleybop Sep. 2 at 3:44 PM
$GPUS $YYGH anyone? Anyone? anything at ALL? $ALZN next?
0 · Reply
Fuddsblood65
Fuddsblood65 Aug. 31 at 1:18 PM
$ALZN Ault has started selling his shares today
0 · Reply
hiwatt
hiwatt Aug. 30 at 6:48 PM
$ALZN Part 2---The Pure Mathematical Impact: +$1.04/share. If the cash influx were divided evenly among equity holders without factoring in legal fees, market speculation, or operational costs, the math shifts because Alzamend has issued additional equity since its 2025 reverse split.Shares Outstanding: According to the latest filings, Alzamend now has 4.83 million shares outstanding.Calculation: Dividing $5,000,000 by 4,830,000 shares yields $1.04 in raw cash per share.Percentage Jump: At a baseline stock price of $1.66, an isolated cash addition of $1.04 equates to a 62.4% increase, theoretically pushing the stock to $2.70.
0 · Reply
hiwatt
hiwatt Aug. 30 at 6:46 PM
$ALZN Part1--"If" Alzn paid Biorasi $1.8M for clinical trial and "If" Alzn has already paid 1.9M in lawyer fees, and"If" Alzn were to be awarded $1.3M in damages, how much would a $5M payout affect stock price?--AI-If Alzamend Neuro (ALZN) wins its ongoing breach of contract trial against Biorasi, LLC, a $5 million gross payout would mathematically add roughly $1.04 per share in value, though the actual market reaction could spark a much more volatile move.Because Alzamend's financial data and share structures have evolved, this updated breakdown uses their latest capital structure and trading price.
0 · Reply
hiwatt
hiwatt Aug. 29 at 6:07 PM
$ALZN Ceo Stephan Jackman testified Friday. I wonder how much they are asking for in damages since Biorasi caused a 2 year delay and shortened the patent life.---Friday, August 28, 2026 217 minutes Bench Trial - Completed Fri 08/28 6:06 PM PAPERLESS Minute Entry for proceedings held before Judge Beth Bloom: Bench Trial completed on 8/28/2026. Witness Aimon Iftikhar continued testimony. Witness Chris O'Brien was placed under oath and testified. Witness Stephan Jackman was placed under oath and testified. Exhibits presented; evidence entered. Each party's closing statement and proposed findings of fact and conclusions of law shall not exceed 40 pages total.
0 · Reply
hiwatt
hiwatt Aug. 28 at 2:13 PM
$ALZN Trial update--Thursday, August 27, 2026 216 minutes Bench Trial - Held Thu 08/27 5:27 PM PAPERLESS Minute Entry for proceedings held before Judge Beth Bloom: Bench Trial held on 8/27/2026. Witness Emily Friedrich continued testimony. Witness Aimon Iftikhar was placed under oath and testified. Exhibits presented; evidence entered. Each party shall submit a closing statement and proposed findings of fact and conclusions of law within 30 days after the filing of trial transcript. The parties are to jointly file a list of exhibits with exhibit numbers by 9/8/2026. This case is in recess until 8/28/2026 at 1:00 PM
0 · Reply
Latest News on ALZN
Alzamend Neuro Proxy statement: Proxy filing

Aug 28, 2026, 8:00 AM EDT - 10 days ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Registration statement: Registration filing

Aug 21, 2026, 8:00 AM EDT - 17 days ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Annual report: Q4 2026

Jul 22, 2026, 7:00 AM EDT - 6 weeks ago

Alzamend Neuro Annual report: Q4 2026


Alzamend Neuro Slides: Corporate presentation

Jul 21, 2026, 7:00 AM EDT - 6 weeks ago

Alzamend Neuro Slides: Corporate presentation


Alzamend Neuro Slides: Corporate presentation

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Alzamend Neuro Slides: Corporate presentation


Alzamend Neuro initiates Phase II trial of AL001 study

2026-03-16T12:15:09.000Z - 5 months ago

Alzamend Neuro initiates Phase II trial of AL001 study


Alzamend Neuro Quarterly report: Q3 2026

Mar 11, 2026, 8:00 AM EDT - 6 months ago

Alzamend Neuro Quarterly report: Q3 2026


Alzamend Neuro Proxy statement: Proxy filing

Feb 26, 2026, 7:00 AM EST - 6 months ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Feb 26, 2026, 7:00 AM EST - 6 months ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Feb 9, 2026, 7:00 AM EST - 7 months ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q2 2026

Dec 9, 2025, 7:00 AM EST - 9 months ago

Alzamend Neuro Quarterly report: Q2 2026


Alzamend Neuro Quarterly report: Q1 2026

Sep 10, 2025, 8:00 AM EDT - 12 months ago

Alzamend Neuro Quarterly report: Q1 2026


Alzamend Neuro Annual report: Q4 2025

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Annual report: Q4 2025


Alzamend Neuro Earnings release: Q4 2025

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Earnings release: Q4 2025


Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update

2025-05-29T20:25:00.000Z - 1 year ago

Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update


Alzamend Neuro initiates first Phase II trial of AL001

2025-05-13T12:17:57.000Z - 1 year ago

Alzamend Neuro initiates first Phase II trial of AL001


Alzamend Neuro trading halted, news pending

2025-05-09T23:50:59.000Z - 1 year ago

Alzamend Neuro trading halted, news pending


Alzamend Neuro announces 1-for-9 reverse stock split

2025-05-08T12:24:11.000Z - 1 year ago

Alzamend Neuro announces 1-for-9 reverse stock split


Alzamend Neuro Announces Reverse Stock Split

May 8, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Reverse Stock Split


Alzamend Neuro Registration statement: Registration filing

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Proxy statement: Proxy filing

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Registration statement: Registration filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Quarterly report: Q3 2025

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Quarterly report: Q3 2025


Alzamend Neuro Proxy statement: Proxy filing

Feb 28, 2025, 7:00 AM EST - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q2 2025

Dec 11, 2024, 7:00 AM EST - 1 year ago

Alzamend Neuro Quarterly report: Q2 2025


Alzamend Neuro Earnings release: Q2 2025

Dec 11, 2024, 7:00 AM EST - 1 year ago

Alzamend Neuro Earnings release: Q2 2025


Alzamend Neuro Quarterly report: Q1 2025

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Quarterly report: Q1 2025


Alzamend Neuro Annual report: Q4 2024

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Annual report: Q4 2024


Alzamend Neuro Registration statement: Registration filing

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Registration statement: Registration filing

Jun 26, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Proxy statement: Proxy filing

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Registration statement: Registration filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Proxy statement: Proxy filing

May 31, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

May 10, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

May 1, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q3 2024

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Quarterly report: Q3 2024


Alzamend Neuro Proxy statement: Proxy filing

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q2 2024

Dec 15, 2023, 7:00 AM EST - 2 years ago

Alzamend Neuro Quarterly report: Q2 2024


Alzamend Neuro Quarterly report: Q1 2024

Sep 13, 2023, 8:00 AM EDT - 2 years ago

Alzamend Neuro Quarterly report: Q1 2024


Alzamend Neuro Proxy statement: Proxy filing

Sep 1, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Aug 24, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Aug 10, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Registration statement: Registration filing

Aug 2, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Annual report: Q4 2023

Jul 27, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Annual report: Q4 2023


Alzamend Neuro Proxy statement: Proxy filing

Mar 31, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q3 2023

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Quarterly report: Q3 2023


Alzamend Neuro Quarterly report: Q2 2023

Dec 12, 2022, 7:00 AM EST - 3 years ago

Alzamend Neuro Quarterly report: Q2 2023


Alzamend Neuro Quarterly report: Q1 2023

Sep 13, 2022, 8:00 AM EDT - 3 years ago

Alzamend Neuro Quarterly report: Q1 2023


Alzamend Neuro Annual report: Q4 2022

Jul 19, 2022, 8:00 AM EDT - 4 years ago

Alzamend Neuro Annual report: Q4 2022


Alzamend Neuro Quarterly report: Q3 2022

Mar 15, 2022, 8:00 AM EDT - 4 years ago

Alzamend Neuro Quarterly report: Q3 2022


Alzamend Neuro Quarterly report: Q2 2022

Dec 13, 2021, 7:00 AM EST - 4 years ago

Alzamend Neuro Quarterly report: Q2 2022


Alzamend Neuro Quarterly report: Q1 2022

Sep 13, 2021, 8:00 AM EDT - 4 years ago

Alzamend Neuro Quarterly report: Q1 2022


Alzamend Neuro Annual report: Q4 2021

Jul 29, 2021, 8:00 AM EDT - 5 years ago

Alzamend Neuro Annual report: Q4 2021


Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 12, 2021, 6:00 AM EDT - 5 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today


Alzamend Neuro Announces Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 5 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering


hiwatt
hiwatt Sep. 7 at 2:49 AM
0 · Reply
hiwatt
hiwatt Sep. 2 at 6:23 PM
$ALZN NEWS--As of 8-25, institutional holdings have jumped to over 57%!!!. After the decline in price in March, institutional dropped to just 3% of the 3.7M shares, or 114K shares. Today with 4.8M shares, institution own 2,750,464 shares, or 57.4%
1 · Reply
austinhaleybop
austinhaleybop Sep. 2 at 3:50 PM
0 · Reply
austinhaleybop
austinhaleybop Sep. 2 at 3:47 PM
$ALZN Todd straight up gangster on ALL his stocks what happened to his YYGH? it's gone!!!??? Joel help me
0 · Reply
austinhaleybop
austinhaleybop Sep. 2 at 3:44 PM
$GPUS $YYGH anyone? Anyone? anything at ALL? $ALZN next?
0 · Reply
Fuddsblood65
Fuddsblood65 Aug. 31 at 1:18 PM
$ALZN Ault has started selling his shares today
0 · Reply
hiwatt
hiwatt Aug. 30 at 6:48 PM
$ALZN Part 2---The Pure Mathematical Impact: +$1.04/share. If the cash influx were divided evenly among equity holders without factoring in legal fees, market speculation, or operational costs, the math shifts because Alzamend has issued additional equity since its 2025 reverse split.Shares Outstanding: According to the latest filings, Alzamend now has 4.83 million shares outstanding.Calculation: Dividing $5,000,000 by 4,830,000 shares yields $1.04 in raw cash per share.Percentage Jump: At a baseline stock price of $1.66, an isolated cash addition of $1.04 equates to a 62.4% increase, theoretically pushing the stock to $2.70.
0 · Reply
hiwatt
hiwatt Aug. 30 at 6:46 PM
$ALZN Part1--"If" Alzn paid Biorasi $1.8M for clinical trial and "If" Alzn has already paid 1.9M in lawyer fees, and"If" Alzn were to be awarded $1.3M in damages, how much would a $5M payout affect stock price?--AI-If Alzamend Neuro (ALZN) wins its ongoing breach of contract trial against Biorasi, LLC, a $5 million gross payout would mathematically add roughly $1.04 per share in value, though the actual market reaction could spark a much more volatile move.Because Alzamend's financial data and share structures have evolved, this updated breakdown uses their latest capital structure and trading price.
0 · Reply
hiwatt
hiwatt Aug. 29 at 6:07 PM
$ALZN Ceo Stephan Jackman testified Friday. I wonder how much they are asking for in damages since Biorasi caused a 2 year delay and shortened the patent life.---Friday, August 28, 2026 217 minutes Bench Trial - Completed Fri 08/28 6:06 PM PAPERLESS Minute Entry for proceedings held before Judge Beth Bloom: Bench Trial completed on 8/28/2026. Witness Aimon Iftikhar continued testimony. Witness Chris O'Brien was placed under oath and testified. Witness Stephan Jackman was placed under oath and testified. Exhibits presented; evidence entered. Each party's closing statement and proposed findings of fact and conclusions of law shall not exceed 40 pages total.
0 · Reply
hiwatt
hiwatt Aug. 28 at 2:13 PM
$ALZN Trial update--Thursday, August 27, 2026 216 minutes Bench Trial - Held Thu 08/27 5:27 PM PAPERLESS Minute Entry for proceedings held before Judge Beth Bloom: Bench Trial held on 8/27/2026. Witness Emily Friedrich continued testimony. Witness Aimon Iftikhar was placed under oath and testified. Exhibits presented; evidence entered. Each party shall submit a closing statement and proposed findings of fact and conclusions of law within 30 days after the filing of trial transcript. The parties are to jointly file a list of exhibits with exhibit numbers by 9/8/2026. This case is in recess until 8/28/2026 at 1:00 PM
0 · Reply
hiwatt
hiwatt Aug. 27 at 2:10 AM
$ALZN Gpus down 40% in last 30 days, Alazn up 30%.
0 · Reply
hiwatt
hiwatt Aug. 27 at 2:08 AM
0 · Reply
hiwatt
hiwatt Aug. 26 at 7:32 PM
$ALZN New podcast interview on BioPharma Catalyst's Biotech Bulls and Breakthroughs with Alzn's CEO, Stephan Jackman.--https://www.youtube.com/watch?v=F163IB5iv9g&t=45s
1 · Reply
gamer2k19
gamer2k19 Aug. 26 at 1:20 PM
1 · Reply
hiwatt
hiwatt Aug. 26 at 3:15 AM
$ALZN Courtesy of Stockinvest.us ---A break-up at the top trend line at $1.65 will firstly indicate a stronger rate of rising. Given the current short-term trend, the stock is expected to rise 33.30% during the next 3 months and, with a 90% probability hold a price between $1.82 and $2.20 at the end of this 3-month period.
0 · Reply
ipaidtoomuch
ipaidtoomuch Aug. 24 at 11:56 AM
$ALZN 98.4 million careful.
1 · Reply
hiwatt
hiwatt Aug. 21 at 6:09 PM
$ALZN A trading trend I've noticed the last few days, the red stock sells have been smaller than the green stock buys. It's almost as if someone is trying to trigger stock stop losses in the after hours and buying back in bigger trades. Today a red 5k sale at the opening and now a 47k green buy.
0 · Reply
hiwatt
hiwatt Aug. 21 at 2:24 AM
0 · Reply
hiwatt
hiwatt Aug. 21 at 2:13 AM
$ALZN Up 22% so far in the month of August. Now the volume is picking up , 244K regular hours, 224K after hours. This thing is getting ready to blow it's top!!!
0 · Reply
ka1954
ka1954 Aug. 20 at 9:42 PM
$ALZN why u fucking idiots don't sell before close? now someone selling 31k in after hours 7% down?
0 · Reply
H3D3RA
H3D3RA Aug. 20 at 5:42 PM
$ALZN still
0 · Reply
hiwatt
hiwatt Aug. 20 at 1:10 AM
$ALZN spent $1.8M on clinical trial cost and 1.9M on court cost so far against Biorasi. Court casre starts back Monday. They need to collect enough to fund AL002 in another clinical trial.
0 · Reply